Antibacterial efficacy of inhalable antibiotic-encapsulated biodegradable polymeric nanoparticles against E. coli biofilm cells

Journal of Biomedical Nanotechnology

Volumn 6, Issue 4, 2010, Pages 391-403

  Cheow, Wean Sin ^a   Chang, Matthew Wook ^a   Hadinoto, Kunn ^a  

^a Nanyang Technological University   (Singapore)

Author keywords

Biofilm; Bronchiectasis; Dry powder inhaler; Inhaled antibiotics; Nanoparticle

Indexed keywords

AERODYNAMIC CHARACTERISTICS; ANTI-BIOFILM; ANTIBACTERIAL EFFICACY; BACTERIAL CELLS; BIODEGRADABLE POLYMERIC NANOPARTICLES; BIOFILM CELLS; BIOFILM INFECTIONS; BIOFILM MATRIX; BRONCHIECTASIS; CIPROFLOXACIN; DRUG ENCAPSULATION EFFICIENCY; DRY POWDER INHALER; E. COLI; EVAPORATION METHOD; EXTRACELLULAR POLYMERIC MATRIXES; FLUOROQUINOLONE ANTIBIOTICS; INHALED ANTIBIOTICS; LEVOFLOXACIN; LOW DOSE; MICRO-SCALES; NANO PARTICULATES; PHYSICAL CHARACTERISTICS; PLANKTONIC CELLS; PLGA NANOPARTICLES; POLYMERIC NANOPARTICLES; SUSTAINED RELEASE;

ANTIBIOTICS; BACTERIOLOGY; BIODEGRADABLE POLYMERS; CELLS; DRUG DOSAGE; EMULSIFICATION; ENCAPSULATION; ESCHERICHIA COLI; NANOPARTICLES;

BIOFILMS;

CIPROFLOXACIN; LEVOFLOXACIN; NANOPARTICLE; POLYCAPROLACTONE; POLYGLACTIN; ANTIINFECTIVE AGENT; DRUG CARRIER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BIOFILM; CELL SURVIVAL; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG RELEASE; DRUG SOLUBILITY; DRY POWDER; EMULSION; ESCHERICHIA COLI; MICRODENSITOMETRY; MINIMUM INHIBITORY CONCENTRATION; NANOEMULSION; NANOENCAPSULATION; PARTICLE SIZE; POLYMERIZATION; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; SPUTUM; ULTRAVIOLET SPECTROPHOTOMETRY; BIODEGRADABLE IMPLANT; CHEMISTRY; DRUG EFFECT; INHALATION; MICROBIOLOGICAL EXAMINATION;

ABSORBABLE IMPLANTS; ANTI-BACTERIAL AGENTS; BIOFILMS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; ESCHERICHIA COLI; INHALATION; LACTIC ACID; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; POLYGLYCOLIC ACID;

EID: 79952999173     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2010.1116     Document Type: Article

References (43)

1. P. S. Stewart, Mechanisms of antibiotic resistance in bacterial biofilms. Int. J. Med. Microbiol. 292, 107 (2002).
2. W. Costerton, R. Veeh, M. Shirtliff, M. Pasmore, C. Post, and G. Ehrlich, The application of biofilm science to the study and control of chronic bacterial infections. J. Clin. Inves. 112, 1466 (2003).
3. A. E. O'Donnell, Bronchiectasis. Chest 134, 815 (2008).
4. I. S. Patel, I. Vlahos, T. M. A. Wilkinson, S. J. Lloyd-Owen, G. C. Donaldson, M. Wilks, R. H. Reznek, and L. A. Wedzicha, Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care 170, 400 (2004).
5. P. R. A. Pauwels and K. F. Rabe, Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 364, 613 (2004).
6. K. Lewis, Persister cells, dormancy and infectious disease. Nat. Rev. Micro. 5, 48 (2007).
7. G. G. Anderson and G. A. O'Toole, Innate and induced resistance mechanisms of bacterial biofilms. Curr. Top. Microbiol. 322, 85 (2008).
8. M. Jd. de Jesús Valle, F. González López, and A. Sánchez Navarro, Pulmonary versus systemic delivery of levofloxacin: The isolated lung of the rat as experimental approach for assessing pulmonary inhalation. Pulm. Pharmacol. Ther. 21, 298 (2008).
9. D. Traini and P. M. Young, Delivery of antibiotics to the respiratory tract: An update. Expert Opin. Drug Deliv. 6, 897 (2009).
10. R. Ramphal, M. Lhermitte, M. Filliat, and P. Roussel, The binding of anti-pseudomonal antibiotics to macromolecules from cystic-fibrosis sputum. J. Antimicrob. Chemoth. 22, 483 (1988).
11. M. Alipour, Z. E. Suntres, M. Halwani, A. O. Azghani, and A. Omri, Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. Plos One 4, e5724 (2009).
12. V. Bataillon, M. Lhermitte, J. J. Lafitte, J. Pommery, and P. Roussel, The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory-diseases. J. Antimicrob. Chemoth. 29, 499 (1992).
13. B. E. Hunt, A. Weber, A. Berger, B. Ramsey, and A. L. Smith, Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob. Agents Ch. 39, 34 (1995).
14. P. Meers, M. Neville, V. Malinin, A. W. Scotto, G. Sardaryan, R. Kurumunda, C. Mackinson, G. James, S. Fisher, and W. R. Perkins, Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemoth. 61, 859 (2008).
15. J. S. Suk, S. K. Lai, Y. Y. Wang, L. M. Ensign, P. L. Zeitlin, M. P. Boyle, and J. Hanes, The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 30, 2591 (2009).
16. N. N. Sanders, S. C. D. Smedt, E. V. Rompaey, P. Simoens, F. D. Baets, and J. Demeester, Cystic fibrosis sputum - A barrier to the transport of nanospheres. Am. J. Resp. Crit. Care 162, 1905 (2000).
17. M. Halwani, S. Hebert, Z. E. Suntres, R. M. Lafrenie, A. O. Azghani, and A. Omri, Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa. Int. J. Pharm. 373, 141 (2009).
18. S. Chono, T. Tanino, T. Seki, and K. Morimoto, Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J. Drug Target 14, 557 (2006).
19. C. Mugabe, M. Halwani, A. O. Azghani, R. M. Lafrenie, and A. Omri, Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Ch. 50, 2016 (2006).
20. A. M. Robinson, M. Bannister, J. E. Creeth, and M. N. Jones, The interaction of phospholipid liposomes with mixed bacterial biofilms and their use in the delivery of bactericide. Colloid Surface A 186, 43 (2001).
21. S. P. Vyas, V. Sihorkar, and S. Jain, Mannosylated liposomes for bio-film targeting. Int. J. Pharm. 330, 6 (2007).
22. V. Balasubramanian, O. Onaca, R. Enea, D. Hughes, and C. Palivan, Protein delivery: from conventional drug delivery carriers to polymeric nanoreactors. Expert Opin. Drug Deliv. 7, 63 (2010).
23. G. Betageri, S. Jenkins, and D. Parsons, Liposome Drug Delivery System, Technomic, Lancaster, PA (1993).
24. G. Fontana, G. Pitarresi, V. Tomarchio, B. Carlisi, and P. L. S. Biagio, Preparation, characterization and in vitro antimicrobial activity of ampicillin-loaded polyethylcyanoacrylate nanoparticles. Biomaterials 19, 1009 (1998).
25. M. E. Page-Clisson, H. Pinto-Alphandary, M. Ourevitch, A. Andremont, and P. Couvreur, Development of ciprofloxacin-loaded nanoparticles: Physicochemical study of the drug carrier. J. Controlled Release 56, 23 (1998).
26. Y I. Jeong, H. S. Na, D. H. Seo, D. G. Kim, H. C. Lee, M. K. Jang, S. K. Na, S. H. Roh, S. I. Kim, and J. W. Nah, Ciprofloxacin-encapsulated poly(DL-lactide-co-glycolide) nanoparticles and its antibacterial activity. Int. J. Pharm. 352, 317 (2008).
27. P. Kobayashi, Airway biofilm disease. Int. J. Antimicrob. Ag 17, 351 (2001).
28. A. C. Fluit, J. Verhoef, F.-J. Schmitz, and S. P. Group, Antimicrobial resistance among isolates cultured from patients hospitalized with lower respiratory tract infection in Europe. Int. J. Infect. Dis. 6, 144 (2002).
29. L. Falgueras, B. Almirante, A. Pahissa, R. P. Martinez, F. Fernandez, and J. M. M. Vazquez, Community-acquired pneumonia by eschericia-coli-a review of 15 cases. Med. Clin. 89, 847 (1987).
30. J. Sung, D. Padilla, L. Garcia-Contreras, J. VerBerkmoes, D. Durbin, C. Peloquin, K. Elbert, A. Hickey, and D. Edwards, Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm. Res. 26, 1847 (2009).
31. R. Misra, S. Acharya, F. Dilnawaz, and S. K. Sahoo, Sustained antibacterial activity of doxycycline-loaded poly(D, L-lactide-coglycolide) and poly(Îμ-caprolactone) nanoparticles. Nanomedicine 4, 519 (2009).
32. J. Harrison, H. Ceri, J. Yerly, C. Stremick, Y. Hu, R. Martinuzzi, and R. Turner, The use of microscopy and three-dimensional visualization to evaluate the structure of microbial biofilms cultivated in the calgary biofilm device. Biol. Proced. Online 8, 194 (2006).
33. H. Ceri, M. E. Olson, C. Stremick, R. R. Read, D. Morck, and A. Buret, The Calgary biofilm device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37, 1771 (1999).
34. E. M. Tiefenbacher, E. Haen, B. Przybilla, and H. Kurz, Photodegradation of some quinolones used as antimicrobial therapeutics. J. Pharm. Sci. 83, 463 (1994).
35. K. Kho and K. Hadinoto, Aqueous re-dispersibility characterization of spray-dried hollow spherical silica nano-aggregates. Powder Technol. 198, 354 (2010).
36. K. Kho and K. Hadinoto, Effects of excipient formulation on the morphology and aqueous re-dispersibility of dry-powder silica nano-aggregates. Colloid Surface A 359, 71 (2010).
37. H. Ishida, Y. Ishida, Y. Kurosaka, T. Otani, K. Sato, and H. Kobayashi, In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa. Antimicrob. Agents Ch. 42, 1641 (1998).
38. H. Hyun, M. S. Kim, S. C. Jeong, Y. H. Kim, S. Y. Lee, H. B. Lee, and G. Khang, Preparation of diblock copolymers consisting of methoxy poly(ethylene glycol) and poly(epsilon-caprolactone)/poly(L-lactide) and their degradation property. Polym. Eng. Sci. 46, 1242 (2006).
39. M. N. Dudley, J. Loutit, and D. C. Griffith, Aerosol antibiotics: Considerations in pharmacological and clinical evaluation. Curr. Opin. Biotech. 19, 637 (2008).
40. J. J. E. Conte, J. A. Golden, M. McIver, and E. Zurlinden, Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. Int. J. Antimicrob. Ag. 28, 114 (2006).
41. P. D. Lister, Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant streptococcus pneumoniae. Postgrad. Med. 120, 46 (2008).
42. K. Hadinoto and W. S. Cheow, Hollow spherical nanoparticulate aggregates as potential ultrasound contrast agent: Shell thickness characterization. Drug Dev. Ind. Pharm. 35, 1167 (2009).
43. K. Hadinoto, Mechanical stability of hollow spherical nano-aggregates as ultrasound contrast agent. Int. J. Pharm. 374, 153 (2009).